Fukui, Tomoya http://orcid.org/0000-0003-4814-4401
Sasaki, Jiichiro
Igawa, Satoshi
Kada, Akiko
Saito, Toshiki I.
Kogure, Yoshihito
Okamoto, Hiroaki
Naoki, Katsuhiko
Article History
Received: 28 December 2021
Accepted: 5 December 2022
First Online: 15 December 2022
Declarations
:
: The National Hospital Organization Nagoya Medical Center Certified Review Board of Clinical Research approved this protocol on December 21, 2020 (approval number: C2020-010). This clinical trial was registered in the Japan Registry of Clinical Trials (registered date: 12 February 2021, registry number: jRCTs041200100). Written informed consent was obtained from all the patients.
: Not applicable.
: This study is conducted with financial support from AstraZeneca K.K.TF received lecture fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., and Ono Pharmaceutical Co. Ltd., and honoraria from Nippon Kayaku Co. Ltd. and Pfizer Japan Inc. JS received lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Bayer Yakuhin Co. Ltd., Kyowa Hakko Kirin Co. Ltd., MSD Co. Ltd., Nippon Kayaku Co. Ltd., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., and Taiho Pharmaceutical Co. Ltd.; research funding from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Yakult Honsha Co. Ltd.; and consulting or advisory fees from A2 Healthcare Corp. SI received lecture fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd., and research funding from Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., and Nippon Kayaku Co. Ltd. YK received lecture fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd., and research funding from MSD K.K. HO received lecture fees from Astellas Pharma Inc., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Novartis Pharma K.K., and MSD K.K., and research funding from AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Merck BioPharma Co. Ltd., and Taiho Pharmaceutical Co. Ltd. KN received lecture fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Co. Ltd., Mochida Pharmaceutical Co. Ltd., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Shionogi & Co. Ltd., and Taiho Pharmaceutical Co. Ltd. AK and TIS declare that they have no competing interests.